Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 18 results.
User Information
Export Records
  1. 1.   MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells
  2. Viola, G.; Bortolozzi, R.; Hamel, E.; Moro, S.; Brun, P.; Castagliuolo, I.; Ferlin, M. G.; Basso, G.
  3. Biochemical Pharmacology. 2012, Jan; 83(1): 16-26.
  1. 2.   Plasma and CNS pharmacokinetics of O(4)-benzylfolic acid (O(4)BF) and metabolite in a non-human primate model
  2. Chuk, M. K.; Cole, D. E.; McCully, C.; Loktionova, N. A.; Pegg, A. E.; Parker, R. J.; Pauly, G.; Widemann, B. C.; Balis, F. M.; Fox, E.
  3. Cancer Chemotherapy and Pharmacology. 2011, Jun; 67(6): 1291-1297.
  1. 3.   Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors
  2. Lee, S.; Yagita, H.; Sayers, T. J.; Celis, E.
  3. Cancer Immunology Immunotherapy. 2010, Jul; 59(7): 1073-1081.
  1. 4.   In vitro comparison of O4-benzylfolate modulated, BCNU-induced toxicity in human bone marrow using CFU-GM and tumor cell lines
  2. Behrsing, H. P.; Furniss, M. J.; Robillard, K. A.; Tomaszewski, J. E.; Parchment, R. E.
  3. Cancer Chemotherapy and Pharmacology. 2010, May; 65(6): 1083-1091.
  1. 5.   The G-protein-coupled formylpeptide receptor FPR confers a more invasive phenotype on human glioblastoma cells
  2. Huang, J.; Chen, K.; Chen, J.; Gong, W.; Dunlop, N. M.; Howard, O. M. Z.; Gao, Y.; Bian, X. W.; Wang, J. M.
  3. British Journal of Cancer. 2010, Mar 16; 102(6): 1052-1060.
  1. 6.   Identifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Anticipation of a Phase I Clinical Trial in Patients with Recurrent Ovarian Cancer
  2. Matthews, K.; Noker, P. E.; Tian, B. H.; Grimes, S. D.; Fulton, R.; Schweikart, K.; Harris, R.; Aurigemma, R.; Wang, M. H.; Barnes, M. N.; Siegal, G. P.; Hemminki, A.; Zinn, K.; Curiel, D. T.; Alvarez, R. D.
  3. Clinical Cancer Research. 2009 15(12): 4131-4137.
  1. 7.   In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide
  2. Kil, W. J.; Cerna, D.; Burgan, W. E.; Beam, K.; Carter, D.; Steeg, P. S.; Tofilon, P. J.; Camphausen, K.
  3. Clinical Cancer Research. 2008 14(3): 931-938.
  1. 8.   What is hidden in the pannexin treasure trove: the sneak peek and the guesswork
  2. Litvin, O.; Tiunova, A.; Connell-Alberts, Y.; Panchin, Y.; Baranova, A.
  3. Journal of Cellular and Molecular Medicine. 2006, Jul-Sep; 10(3): 613-634.
  1. 9.   Phase I trial of temozolomide plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma
  2. Quinn, J. A.; Desjardins, A.; Weingart, J.; Brem, H.; Dolan, M. E.; Delaney, S. M.; Vredenburgh, J.; Rich, J.; Friedman, A. H.; Reardon, D. A.; Sampson, J. H.; Pegg, A. E.; Moschel, R. C.; Birch, R.; McLendon, R. E.; Provenzale, J. M.; Gururangan, S.; Dancey, J. E.; Maxwell, J.; Tourt-Uhlig, S.; Herndon, J. E.; Bigner, D. D.; Friedman, H. S.
  3. Journal of Clinical Oncology. 2005, OCT 1; 23(28): 7178-7187.
  1. 10.   Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O-6-benzylguanine
  2. Fishel, M. L.; Ganicsik, M. P.; Delaney, S. M.; Zuhowski, E. G.; Maher, V. M.; Karrison, T.; Moschel, R. C.; Egorin, M. J.; Dolan, M. E.
  3. Cancer Chemotherapy and Pharmacology. 2005, APR; 55(4): 333-342.
  1. 11.   Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain
  2. Zagzag, D.; Salnikow, K.; Chiriboga, L.; Yee, H.; Lan, L.; Ali, M. A.; Garcia, R.; Demaria, S.; Newcomb, E. W.
  3. Laboratory Investigation. 2005, MAR; 85(3): 328-341.
  1. 12.   Silencing the formylpeptide receptor FPR by short-interfering RNA
  2. Le, Y. Y.; Iribarren, P.; Zhou, Y.; Gong, W. H.; Hu, J. Y.; Zhang, X.; Wang, J. M.
  3. Molecular Pharmacology. 2004, OCT; 66(4): 1022-1028.
  1. 13.   Brain tumor cell lines resistant to O-6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O-6 -alkylguanine-DNA alkyltransferase mutations
  2. Bacolod, M. D.; Johnson, S. P.; Pegg, A. E.; Dolan, M. E.; Moschel, R. C.; Bullock, N. S.; Fang, Q. M.; Colvin, O. M.; Modrich, P.; Bigner, D. D.; Friedman, H. S.
  3. Molecular Cancer Therapeutics. 2004, SEP; 3(9): 1127-1135.
  1. 14.   Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XLAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database
  2. Nikolovska-Coleska, Z.; Xu, L.; Hu, Z. J.; Tomita, Y.; Li, P.; Roller, P. P.; Wang, R. X.; Fang, X. L.; Guo, R. B.; Zhang, M. C.; Lippman, M. E.; Yang, D. J.; Wang, S. M.
  3. Journal of Medicinal Chemistry. 2004 47(10): 2430-2440.
  1. 15.   O-6-benzylguanine-mediated enhancement of chemotherapy
  2. Friedman, H. S.; Keir, S.; Pegg, A. E.; Houghton, P. J.; Colvin, O. M.; Moschel, R. C.; Bigner, D. D.; Dolan, M. E.
  3. Molecular Cancer Therapeutics. 2002 1(11): 943-948.
  1. 16.   Debenzylation of O-6-benzyl-8-oxoguanine in human liver: implications for O-6-benzylguanine metabolism
  2. Long, L.; Moschel, R. C.; Dolan, M. E.
  3. Biochemical Pharmacology. 2001 61(6): 721-726.
  1. 17.   Inactivation of O-6-alkylguanine-DNA alkyltransferase by 8- substituted O-6-benzylguanine analogs in mice
  2. Ewesuedo, R. B.; Wilson, L. R.; Friedman, H. S.; Moschel, R. C.; Dolan, M. E.
  3. Cancer Chemotherapy and Pharmacology. 2001 47(1): 63-69.
  1. 18.   Comparative molecular genetic profiles of anaplastic astrocytomas glioblastomas multiforme and their subsequent recurrences
  2. Saxena, A.; Shriml, L. M.; Dean, M.; Ali, I. U.
  3. Oncogene. 1999 18(6): 1385-1390.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel